Iovance Biotherapeutics Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +399.6% | +13,699.0% | +60.6% | |
| – | – | – | – | -100.0% | – | -98.1% | +1,032.4% | -2.1% | -2.7% | +0.4% | +749.7% | +7.3% | +60.5% | +51.2% | -49.1% | +1,052.9% | -94.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +539.3% | |
| – | – | – | – | -5.7% | -19.7% | +103.5% | +471.9% | +81.2% | +155.4% | +39.4% | +66.3% | +21.5% | +28.4% | +13.8% | +16.7% | -17.9% | +6.4% | |
| – | -43.5% | +5,135.5% | +2,453.3% | -66.4% | -28.1% | +100.6% | +32.7% | +106.6% | -17.0% | +33.7% | +43.7% | +47.4% | +39.0% | +24.4% | -73.4% | +87.0% | +194.1% | |
| – | -74.7% | +5,546.9% | +135.0% | +324.5% | +121.2% | -85.0% | +929.9% | +92.5% | +73.2% | +38.1% | +61.3% | +26.6% | +30.8% | +16.4% | +13.1% | -3.5% | +51.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -100.0% | – | -98.7% | +3,433.6% | -100.0% | – | – | – | – | -80.9% | +561.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +484.9% | -100.0% | – | -100.0% | – | – | – | – | -324.1% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.